Background: Unexplained hepatitis C virus (HCV) relapse after treatment by DAAs (sofosbuvir and daclatasvir) is due to several factors, one of them is liver stiffness. We studied this factor trying to avoid relapse of HCV after treatment in the future and assess the treatment role on liver stiffness regression. Aim: Prevention of HCV relapse after treatment by direct acting antiviral drugs. Patients and methods: This cohort research was conducted at Alahrar Teaching Hospital (Zagazig City, Sharkia Governorate). Patients with age > 18 years old with HCV infection (diagnosed by HCV PCR), after received treatment (relapsers) by (sofosbuvir and daclatasvir) were included in the study. All cases underwent full history taking, laboratory investigations, thorough physical examination and liver fibrosis evaluation by fibroscan. Results: Liver stiffness measurement (LSM), fibrosis 4 (FIB 4), and AST to Platelet Ratio Index (APRI) scores were significantly different between SVR and non-SVR groups before and after treatment. Conclusion: Improved liver fibrosis measures (LSM, FIB 4, and APRI scores) are associated with the successful treatment of chronic HCV with novel direct-acting antivirals. In addition, elevated LSM prior to therapy can be predictive of non-response.